

# DRUG METABOLISM AND DISPOSITION



**A Publication of the  
American Society for Pharmacology  
and Experimental Therapeutics**

 **BALTIMORE, USA**  
**APRIL 2007**

A Simcyp Sponsored Seminar  
Wednesday 4<sup>th</sup> April 2007

Register before  
February 15<sup>th</sup> &  
**SAVE 33%**

# **ADME in Drug Development: Bridging DM-PK-PD Using Modelling and Simulation**

Register free as part of attendance at our

## **Hands-on Workshops on "Concepts" and "Applications" of Population based *In Vitro* - *In Vivo* Extrapolation of ADME Properties**

For more information on this and other International Workshops and Seminars please see

<http://www.simcyp.com/docs/workshops.htm>

2<sup>nd</sup> - 3<sup>rd</sup> April 2007  
Concepts Workshop

5<sup>th</sup> - 6<sup>th</sup> April 2007  
Applications Workshop

**Baltimore Marriott Waterfront Hotel, Baltimore, USA**

The workshops will centre around practical examples demonstrating how data generated during drug discovery and pre-clinical drug development can be used to predict:

- Metabolic drug clearance (CL)
- Metabolic drug-drug interactions (DDIs)
- Gut first-pass metabolism
- Oral drug absorption including the effect of efflux transporters
- Drug distribution to different organs
- Plasma drug concentration-time profiles
- Metabolic CL and DDIs in specific populations (*pediatric, ethnic groups, disease groups*)

The main emphasis will be on assessing population variability and optimizing the design of clinical studies within the framework of whole body physiologically-based pharmacokinetics (WB PBPK).

### **Speakers in the Seminar include:**

**David J Greenblatt**, Dept. of Pharmacol & Exptl Therapeutics, **Tufts University**

**Micaela Reddy**, Research Scientist, **Roche, Palo Alto**

**Amin Rostami**, Reader in Clinical Pharmacology and Drug Metabolism, **Univ Sheffield** and Director of Scientific R&D, **Simcyp Limited**

**Ed LeCluyse**, Chief Scientific Officer, **Cellzdirect**

**David Plowchalk**, Associate Research Fellow, **Pfizer, Groton**

**Steve Toon**, Executive Director, **Simcyp Limited, Sheffield**

**Sean Ekins**, Senior Vice President, **Arnold Consulting Technologies LL**

**Joseph Polli**, Section Manager, DMPK, **GlaxoSmithKline, RTP**

**Rajesh Krishna**, Head, Quantitative Clinical Pharmacology, **Merck, Rahway**



Enzyme kinetics - pharmacokinetics - and beyond



# Take a Dip In Our Pool



## *LiverPool™ 5- and 10- Donor Pooled Cryopreserved Human Hepatocytes*



In Vitro Technologies, the originator of cryopreserved hepatocytes, now offers LiverPool™ (patent pending) 5- and 10- Donor Pooled Cryopreserved Human Hepatocytes for use in toxicity, apoptosis, and metabolism studies.

- ◆ **Ease of use.** Available in 5- and 10-donor pooled lots.
- ◆ **Convenience.** Increase your available research time by eliminating the need to pool individual vials.
- ◆ **Cost savings.** Decrease the number of vials purchased.
- ◆ **Ready to use.** Pooled lots fully characterized and available for immediate delivery.
- ◆ **Convenient packaging.** Vial contains 5 million viable cells.

---

For more information regarding this, or any In Vitro Technologies product, call toll free **888-488-3232**

E-mail: **[info@invitrotech.com](mailto:info@invitrotech.com)**

Web: **[www.invitrotech.com](http://www.invitrotech.com)**